60,000 MiraCare Tests Destined for New Market Vertical HALIFAX, Dec. 21 /PRNewswire-FirstCall/ -- MedMira Inc., ("MedMira") (TSX Venture: MIR, NASDAQ: MMIRF) the global market leader in premium rapid diagnostic solutions, announced today that it has received an order for 60,000 MiraCare(TM) Rapid HIV Tests (MiraCare(TM)) from its distributor, Goodman Medical Supplies Ltd. (Goodman). This is the largest order received to date for the MiraCare(TM) test, which was launched in early 2005 in Hong Kong and Macao. This particular order is destined for a new market vertical. "This order represents significant and continued growth in Asia, a strategic global market for MedMira," said Stephen Sham, chairman and CEO, MedMira. "Using Hong Kong and Macao as the launching pad has proven successful and we are now poised to take MiraCare(TM) into global markets where customers are demanding quality over-the-counter (OTC) rapid HIV tests." With CE mark approval in the final stages, MedMira will soon be launching MiraCare(TM) in the European Union market. The company is also exploring opportunities in the US market where demand is increasing for a reliable, quality OTC rapid HIV test. MiraCare(TM) is sold as a complete test kit with all components required for an individual to perform the test. The test is highly accurate and uses a fingerstick whole blood specimen, one of the most reliable testing specimens for home-use diagnostics. MiraCare(TM) takes less than three minutes to perform and provides test results instantly. About MedMira MedMira is the leading global manufacturer and marketer of in vitro flow- through rapid diagnostic tests. MedMira's tests provide reliable, rapid diagnosis in just 3 minutes for the detection of human antibodies in human serum, plasma or whole blood for diseases such as HIV and hepatitis C. The United States FDA and the SFDA in the People's Republic of China have approved MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests, respectively. MedMira's Reveal(R) G2 and MiraWell(R) rapid HIV tests are currently used in clinical laboratories, hospitals, and clinics where professional counselling and patient treatment are immediately available. The MiraCare(TM) Rapid HIV Antibody Test, MedMira's over-the-counter (OTC) product, is available in pharmacies throughout Hong Kong and Macao Special Administrative Regions, in the People's Republic of China. MedMira delivers rapid diagnostic solutions to healthcare communities around the globe. Its corporate offices and manufacturing facilities are located in Halifax, Nova Scotia, Canada with a representative office in Guilin, China. This news release contains forward-looking statements, which involve risk and uncertainties and reflect the company's current expectation regarding future events. Actual events could materially differ from those projected herein and depend on a number of factors including, but not limited to, changing market conditions, successful and timely completion of clinical studies, uncertainties related to the regulatory approval process, establishment of corporate alliances and other risks detailed from time to time in the company quarterly filings. The TSX Venture Exchange has not reviewed and does not accept responsibility for the adequacy or accuracy of this statement. For more information visit MedMira's website at http://www.medmira.com/. DATASOURCE: MedMira Inc. CONTACT: Dr. James Smith, Investor Relations, Tel: (902) 450-1588, E-mail: ; Andrea Young, Corporate Communications, Tel. (902) 450-1588, Email:

Copyright